Recent findings from a 4-year study reveal that TransCon® PTH (palopegteriparatide) exhibits a sustained and effective response in treating adults with hypoparathyroidism. The long-term data, released by TransCon PTH, supports its potential to enhance the quality of life for patients suffering from this rare endocrine disorder, which is characterized by low levels of calcium in the blood. The findings offer promising insights into stabilizing calcium levels, reducing the dependence on standard calcium and active vitamin D treatments, and alleviating symptoms associated with the disease. Patients who participated in the study demonstrated significant improvements in their condition, underscoring the efficacy of TransCon PTH therapy as a transformative option. As a result, this therapy may redefine current treatment paradigms, offering a new life-changing solution for patients and healthcare providers. Such advancements emphasize the importance of continued research and innovation in the field of endocrine disorders.
GlobeNewswireNew data shows increase in children accessing food banks in Manitoba as overall usage rises
October 22, 2026
New data reveals a troubling rise in the number of children accessing food banks across Manitoba, highlighting growing food insecurity in the province. The latest